Mark Lin, MD
Gastroenterology · Tucson, AZNPI 1366594749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 27.0% of the total. 2025 is the largest year on record at $1,084, 2.3 times the $467 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in AZ, where the typical reported total is $3,568.
Across 124 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$793
- Takeda Pharmaceuticals U.S.A., Inc.$486
- Pfizer$224
- Johnson & Johnson$215
- Medtronic$174
- Phathom Pharmaceuticals, Inc.$134
- plus $909 from 23 others
Across 4 payments — averaging $1236.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
What the payments were for
- Food & beverage$2,922100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $793 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $486 |
| Pfizer | 10 | $224 |
| Johnson & Johnson | 13 | $215 |
| Medtronic | 1 | $174 |
| Phathom Pharmaceuticals, Inc. | 14 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Intercept Pharmaceuticals, Inc. | 6 | $113 |
| Sanofi | 4 | $104 |
| UCB, Inc. | 2 | $70 |
| Ardelyx, Inc. | 2 | $54 |
| Braintree Laboratories, Inc. | 3 | $52 |
| Amgen | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Bristol Myers Squibb | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $28 |
| Sandoz | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Mylan Institutional Inc. | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Organon | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| QOL Medical, LLC | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,935 in reported general payments places this provider in the 40th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 52 | $609,514 |
| StelaraUstekinumab | 17 | $462,636 |
| OcalivaObeticholic Acid | 12 | $112,039 |
| CreonLipase/Protease/Amylase | 28 | $112,038 |
| ZenpepLipase/Protease/Amylase | 18 | $39,311 |
| LinzessLinaclotide | 30 | $31,286 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 145 | $23,981 |
| Mesalamine | 28 | $16,477 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 211 | $13,462 |
| MotegrityPrucalopride Succinate | 12 | $13,091 |
| TrulancePlecanatide | 22 | $12,045 |
| Budesonide DrBudesonide | 44 | $4,952 |
| Omeprazole | 303 | $3,406 |
| Pantoprazole Sodium | 207 | $2,711 |
| Balsalazide Disodium | 11 | $2,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $215 | $462,63617 claims |
| AbbVieCreon, Linzess | $793 | $143,32458 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $113 | $112,03912 claims |
| Aimmune Therapeutics, Inc.Zenpep | $28 | $39,31118 claims |
| Braintree Laboratories, Inc.Sutab | $52 | $23,981145 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $486 | $13,09112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $14 | $12,04522 claims |
| SandozLansoprazole | $27 | $26012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Tucson
- Joel BrillParadise Valley$847K
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Neil SharmaGilbert$405K
- Chirag TrivediSun City$400K
- David LeffMesa$377K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.